163 related articles for article (PubMed ID: 33078278)
1. Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response.
Shi P; Zha J; Feng J; Jiang Z; Zhao H; Deng M; Liao N; Li P; Jiang Y; Song H; Xu B
Stem Cell Rev Rep; 2021 Apr; 17(2):616-627. PubMed ID: 33078278
[TBL] [Abstract][Full Text] [Related]
2. Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors.
Liu Y; Chen F; Wang S; Guo X; Shi P; Wang W; Xu B
Cell Death Dis; 2013 Dec; 4(12):e948. PubMed ID: 24309935
[TBL] [Abstract][Full Text] [Related]
3. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
5. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
6. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
7. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
[TBL] [Abstract][Full Text] [Related]
8. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
9. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
11. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
[TBL] [Abstract][Full Text] [Related]
12. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
13. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
14. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
15. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.
Carter BZ; Mak DH; Shi Y; Fidler JM; Chen R; Ling X; Plunkett W; Andreeff M
Leukemia; 2012 Mar; 26(3):443-50. PubMed ID: 21904380
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.
Li L; Osdal T; Ho Y; Chun S; McDonald T; Agarwal P; Lin A; Chu S; Qi J; Li L; Hsieh YT; Dos Santos C; Yuan H; Ha TQ; Popa M; Hovland R; Bruserud Ø; Gjertsen BT; Kuo YH; Chen W; Lain S; McCormack E; Bhatia R
Cell Stem Cell; 2014 Oct; 15(4):431-446. PubMed ID: 25280219
[TBL] [Abstract][Full Text] [Related]
18. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
19. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
20. Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells.
Krastinaite I; Charkavliuk S; Navakauskiene R; Borutinskaite VV
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
